Apogee Therapeutics, Inc. (APGE)

NGM – Real vaqt narxi. Valyuta: USD

82.93

-1.67 (-1.97%)

Yopilishda: May 12, 2026, 4:00 PM EDT

82.61

-0.32 (-0.39%)

Bozor oldidan: May 13, 2026, 7:33 AM EDT

11.05.2026

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD) expected later this year: - APEX Phase 2 Part A 52-week data demonstrated durable maintenance and improved efficacy over time with every 3- and 6-month dosing in moderate-to-severe AD - APEX Phase 2 Part B 16-week data in AD expected in Q2 2026 - Following positive Phase 1b asthma results earlier this year, expansion plans are underway with additional trial details for asthma and eosinophilic esophagitis (EoE) expected later this year Strong cash position of $1.3B following successful public equity offering extending runway into 2029, through planned BLA filing for AD, subject to regulatory alignment SAN FRANCISCO and BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today provided pipeline progress and reported first quarter 2026 financial results. “We are off to a rapid start in 2026, reflecting the team's relentless focus on execution.

26.03.2026

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 750,000 additional shares, at a public offering price per share of $70.00. The aggregate gross proceeds to Apogee from the offering were approximately $403 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee.

26.03.2026

Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors

The CEO of Apogee Therapeutics reported selling 20,000 shares of the company for approximately $1.50 million on March 11, 2026. This disposition represented 1.71% of Henderson's direct holdings at the time of the transaction, as reported in the Form 4.

25.03.2026

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price per share of $70.00. The aggregate gross proceeds to Apogee from the offering are expected to be approximately $350 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee. The offering is expected to close on March 26, 2026, subject to the satisfaction of customary closing conditions. In addition, Apogee has granted the underwriters an option for a period of 30 days to purchase up to an additional 750,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.

24.03.2026

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics jumps 20% as 52-week phase II Part A data show sustained efficacy of its AD candidate, zumilokibart, with durable responses and infrequent dosing boosting its promise.

24.03.2026

Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone

Apogee Therapeutics, Inc. maintains a Strong Buy rating following positive 52-week maintenance data for zumilokibart in moderate-to-severe Atopic Dermatitis [AD]. APGE's half-life extended monoclonal antibody technology enables less frequent dosing, with Q3M and Q6M regimens showing EASI-75 responses of 75% and 85% in Week 16 responders. Upcoming catalysts include 16-week induction data from Part B of the phase 2 APEX trial in Q2 2026 and potential phase 3 initiation in H2 2026.

23.03.2026

Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript

Videolar

No Data

There is no data to display

Press-relizlar

11.05.2026

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

26.03.2026

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

25.03.2026

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

23.03.2026

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

SAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced that it has commenced an underwritten public offering of $300 million of shares of its common stock. In addition, Apogee expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares of common stock are being offered by Apogee.

Apogee Therapeutics, Inc. (APGE)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone

Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript

Videolar

No Data

Press-relizlar

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone

Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript

Videolar

No Data

Press-relizlar

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

Search stocks

Apogee Therapeutics, Inc. (APGE)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone

Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript

Videolar

No Data

Press-relizlar

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone

Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript

Videolar

No Data

Press-relizlar

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering